



Docket No.: 030682.0001-US01
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
David Bebbington et al.

Application No.: 10/632,428

Confirmation No.: 4377

Filed: August 1, 2003

Art Unit: 1624

For: PYRAZOLE COMPOUNDS USEFUL AS
PROTEIN KINASE INHIBITORS

Examiner: J. H. Johnsen

REQUEST FOR CORRECTED FILING RECEIPT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Applicants hereby request that a corrected official Filing Receipt be issued in the above-identified patent application. The official Filing Receipt received by Applicants omits in error the following information, which should appear under the section "Domestic Priority data as claimed by applicant":

--This application is a continuation of 10/025,164, filed 12/19/2001, which claims priority to 60/286,949, filed 04/27/2001 and to 60/257,887, filed 12/21/2000.--

A copy of the official Filing Receipt received by Applicants, marked up to show the requested correction, is enclosed herewith.

Claiming of priority to Provisional Application Nos. 60/286,949 and 60/257,887 was made in the first paragraph of the original specification. The present application was identified as a continuing application of Application No. 10/025,164 on the Utility Patent Application Transmittal filed on August 1, 2003 (copy enclosed), as well as on the Form PTO-1449

accompanying the Information Disclosure Statement filed on August 1, 2003 (copy enclosed). As noted on the Form PTO-1449, Application No. 10/025,164 is relied upon for an earlier filing date under 35 U.S.C. § 120.

Further, Applicants claimed priority to the above-identified two provisional applications and the above-identified parent nonprovisional application in the Preliminary Amendment and the Application Data Sheet filed on November 21, 2003. A copy of each of these documents is enclosed.

Also enclosed is a Supplemental Application Data Sheet reflecting the domestic priority data and the assignee for this application.

Applicants respectfully request the issuance of a corrected official Filing Receipt indicating the complete priority information for this application. Additionally, Applicants request that all pertinent U.S. Patent and Trademark Office records relating to the subject application be changed accordingly.

Dated: August 3, 2006

Respectfully submitted,

By 

Paul J. Berman

Registration No.: 36,744

Melody H. Wu

Registration No.: 52,376

COVINGTON & BURLING LLP

1201 Pennsylvania Avenue, N.W.

Washington, DC 20004-2401

(202) 662-6000

Attorneys for Applicants



UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/632,428	08/01/2003	1624	3694	VPI/00-130-03 CON US		28	2

CONFIRMATION NO. 4377

Andrea L. C. Robidoux
Vertex Pharmaceuticals Incorporated
130 Waverly Street
Cambridge, MA 02139-4242

FILING RECEIPT



OC000000011148867

Date Mailed: 10/31/2003

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

David Bebbington, Newbury, UNITED KINGDOM;
Jean-Damien Charrier, Wantage, UNITED KINGDOM;
Julian Golec, Swindon, UNITED KINGDOM;
Andrew Miller, Didcot, UNITED KINGDOM;
Ronald Knegt, Abingdon, UNITED KINGDOM;

Domestic Priority data as claimed by applicant

--This application is a continuation of 10/025,164, filed 12/19/2001, which claims priority to 60/286,949, filed 04/27/2001 and 60/257,887, filed 12/21/2000.--

Foreign Applications

If Required, Foreign Filing License Granted: 10/30/2003

Projected Publication Date: 02/03/2005

Non-Publication Request: No

Early Publication Request: No

Title

Pyrazole compounds useful as protein kinase inhibitors

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).



Please type a plus sign (+) inside this box → ☐

Approved for use through 10/31/2002. OMB 0651-0032

Under the Paperwork Reduction Act of 1995, no persons are required to furnish information to the collection of information unless it displays a valid OMB control number.

UTILITY PATENT APPLICATION TRANSMITTAL <small>(Only for new nonprovisional applications under 37 CFR 1.53(b))</small>	Attorney Docket No.	VPI/00-130-03 CON US
	First Inventor	David Bebbington
	Title	Pyrazole Compounds Useful as Protein Kinases Inhibitors
	Express Mail Label No.	EV 317 172 762 US

APPLICATION ELEMENTS <small>See MPEP chapter 600 concerning utility patent application contents.</small>	ADDRESS TO: MS Patent Application Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450
--	---

<p>1. <input type="checkbox"/> Fee Transmittal Form (e.g., PTO/SB/17) <small>(Submit an original, and a duplicate for fee processing)</small></p> <p>2. <input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27.</p> <p>3. <input checked="" type="checkbox"/> Specification <small>[Total Pages 333]</small> <small>(preferred arrangement set forth below)</small> - Descriptive title of the invention - Cross Reference to Related Applications - Statement Regarding Fed sponsored R & D - Reference to sequence listing, a table, or a computer program listing appendix - Background of the Invention - Brief Summary of the Invention - Brief Description of the Drawings (if filed) - Detailed Description - Claim(s) - Abstract of the Disclosure</p> <p>4. <input type="checkbox"/> Drawing(s) (35 U.S.C. 113) <small>[Total Sheets]</small></p> <p>5. Oath or Declaration <small>[Total Pages 4]</small> a. <input type="checkbox"/> Newly executed (original or copy) b. <input checked="" type="checkbox"/> Copy from a prior application (37 CFR 1.63(d)) <small>(for continuation/divisional with Box 18 completed)</small> i. <input type="checkbox"/> DELETION OF INVENTOR(S) <small>Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).</small></p> <p>6. <input type="checkbox"/> Application Data Sheet. See 37 CFR 1.76</p>	<p>7. <input type="checkbox"/> CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)</p> <p>8. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary) a. <input type="checkbox"/> Computer Readable Form (CRF) b. Specification Sequence Listing on: i. <input type="checkbox"/> CD-ROM or CD-R (2 copies); or ii. <input type="checkbox"/> paper c. <input type="checkbox"/> Statements verifying identity of above copies</p>
--	--

ACCOMPANYING APPLICATIONS PARTS	
9. <input type="checkbox"/> Assignment Papers (cover sheet & document(s))	
10. <input type="checkbox"/> 37 CFR 3.73(b) Statement <input type="checkbox"/> Power of Attorney <small>(when there is an assignee)</small>	
11. <input type="checkbox"/> English Translation Document (if applicable)	
12. <input type="checkbox"/> Information Disclosure Statement (IDS)/PTO-1449 <input type="checkbox"/> Copies of IDS Citations	
13. <input type="checkbox"/> Preliminary Amendment	
14. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) <small>(Should be specifically itemized)</small>	
15. <input type="checkbox"/> Certified Copy of Priority Document(s) <small>(if foreign priority is claimed)</small>	
16. <input type="checkbox"/> Nonpublication Request under 35 U.S.C. 122 (b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent.	
17. <input checked="" type="checkbox"/> Other: Express Mail Page	

18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.: 10/025,164

Prior application information: Examiner Sudhaker B. Patel Group / Art Unit: 1624

For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The Incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.


19. CORRESPONDENCE ADDRESS

☐ Customer Number or Bar Code Label

27916

or ☒ Correspondence address below

Name	Andrea L. C. Robidoux Vertex Pharmaceuticals Incorporated				
Address	130 Waverly Street				
City	Cambridge	State	Massachusetts	Zip Code	02139-4242
Country	USA	Telephone	(617) 444-6731	Fax	(617) 444-6483
Name (Print/Type)	Andrea L. C. Robidoux		Registration No. (Attorney/Agent)	47,902	
Signature			Date	August 1, 2003	



Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	Not Yet Assigned
	Filing Date	Herewith
	First Named Inventor	David Bebbington
	Group Art Unit	Sudhaker B. Patel
	Examiner Name	1624
	Attorney Docket Number	VPI/00-130-03 CON US

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	A1*	US 2001/0018436	30-Aug-2001	Tularik Inc.			
	A2*	2002/0065270	05/30/2002	Bristol-Myers Squibb Company			
	A3*	10/025,164		Vertex Pharmaceuticals Incorporated			19-Dec-2001

FOREIGN PATENT DOCUMENTS						
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No	
	B1*	WO 02/18346	Pfizer Products, Inc.	07-Mar-2002		
	B2*	WO 00/39101	Astrazeneca UK Limited	06-Jul-2000		
	B3*	WO 00/21955	Zeneca Limited	20-Apr-2000		


OTHER NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, U.S.S.N. 10/025,164, filed December 19, 2001, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.



VPI/00-130-03 CON US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Bebbington, et al.

Serial No.: 10/632,428

Filing Date: August 1, 2003 (01.08.03)

For: PYRAZOLE COMPOUNDS USEFUL AS PROTEIN
KINASE INHIBITORS

Cambridge, Massachusetts
November 18, 2003

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

PRELIMINARY AMENDMENT UNDER 37 C.F.R. §1.115

Sir/Madam:

Prior to examination on the merits, please amend the above-identified application
as follows:

IN THE SPECIFICATION:

On page 1, immediately after the title, please insert:

--- CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of co-pending United States Patent Application serial number 10/025,164, filed December 19, 2001, which claims priority to United States Provisional Patent Application 60/257,887, filed December 21, 2000, and United States Provisional Patent Application 60/286,949, filed April 27, 2001, the entirety of which are incorporated herein by reference. ---


REMARKS

Applicants amend the Cross Reference to Related Applications to set forth the priority claim in the above-identified application.

This amendment adds no new matter.

Applicants respectfully request that the Examiner enter the indicated amendment prior to substantive examination of this application.

Respectfully submitted,



Andrea L. C. Robitoux (Reg. No. 47,902)
Agent for Applicants
C/O Vertex Pharmaceuticals Inc.
130 Waverly St.
Cambridge, MA 02139-4242
Tel: (617)444-6731
Fax: (617)444-6483



VPI/00-130-03 CON US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Bebbington, et al.
Serial No.: 10/632,428
Filing Date: August 1, 2003 (01.08.03)
For: PYRAZOLE COMPOUNDS USEFUL AS PROTEIN
KINASE INHIBITORS

Cambridge, Massachusetts
November 18, 2003

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

APPLICATION DATA SHEET

Sir/Madam:

Applicants submit this Application Data Sheet relating to the above-identified application pursuant to 37 C.F.R. §1.76 (c)(1).


Specifically, this Application Data Sheet is submitted in order to set forth the priority claim for the above identified application.

The correct priority claim information for the present application is as follows:

--- This application is a continuation of co-pending United States Patent Application serial number 10/025,164, filed December 19, 2001, which claims priority to United States Provisional Patent Application 60/257,887, filed December 21, 2000, and United States Provisional Patent Application 60/286,949, filed April 27, 2001, the entirety of which are incorporated herein by reference. ---

Applicants believe that no additional fees are due at this time however, the Commissioner is hereby authorized to charge payment of additional fees required under 37 C.F.R. §1.16 in connection with the paper transmitted herewith, or credit any overpayment of same, to Deposit Account No. 50-0725.

Respectfully submitted,



Andrea L.C. Robidoux (Reg.No. 47,902)

Agent for Applicants

C/O Vertex Pharmaceuticals, Inc.

130 Waverly Street

Cambridge, MA 02139-4242

Tel.: (617) 444-6731

Fax.: (617) 444-6483